Cancer Drugs Thwart Ebola In Lab | WAMU 88.5 - American University Radio

NPR : News

Filed Under:

Cancer Drugs Thwart Ebola In Lab

Ebola is one virus you never want to catch. Ever.

After some aches and a fever, many infected people develop uncontrolled bleeding. The mortality rates from Ebola infection can run as high as 90 percent.

There's no cure for Ebola. But a group of scientists is exploring whether some drugs already approved to treat cancer might help tame the virus.

Sounds wild. But there's a reason — and now some evidence — to think it might work.

To reproduce, the Ebola virus needs the help of cells it invades. And a couple of cancer drugs tweak a human protein that new copies of the virus use to leave their host cells so they can infect others.

The tested drugs — Gleevec and Tasigna, both sold by Novartis — are called tyrosine kinase inhibitors. Tyrosine kinases are enzymes that put a phosphate group on a particular amino acid. Amino acids, as you might remember from high school biology, are the building blocks of proteins.

When a phosphate group gets attached to the right tyrosine block on the right protein, it changes the shape and function of the protein. And that might change everything when it comes to Ebola.

"Proteins are like little machines," says Emory University's Dan Kalman, one of the researchers. "As with a machine, they can be turned or turned off. The switch for turning things on or off is a modification. And one of those modifications is a phosphate group."

In some cancers, the tyrosine kinases help trigger the uncontrolled division of cells. Gleevec and Tasigna help stop that.

When it comes to Ebola, the researchers think drugs like these could turn off a transport protein and could keep new viruses bottled up inside cells.

The Ebola lab work using collections of human cells was published in the latest issue of Science Translational Medicine. It showed that the drugs dramatically decrease the ability of Ebola to replicate. "The effect was quite pronounced," Kalman told Shots.

And, if the theory holds, such a reduction might be enough to allow an infected person's immune system to mop up the Ebola viruses.

"Ebola is a very nasty infection," Kalman says. "The whole concept of containing the disease in a local group before it spreads all over the planet is something clearly we want to do."

The next step will be to see if the drugs can make a difference in animal experiments.

Copyright 2012 National Public Radio. To see more, visit http://www.npr.org/.

NPR

Vaccine Controversies Are As Social As They Are Medical

In writing her new book On Immunity, Eula Biss found that questions about vaccination touch on attitudes about environmentalism, citizenship and trust in the government.
NPR

Millennial Jews Do An About-Face, Start Keeping Kosher

According to a 2013 Pew Research Center study, nearly a fourth of millennial Jews are keeping kosher. That's almost twice the rate of their baby boomer parents.
NPR

Napolitano: ISIS Was One Of Many Similar Threats We Were Tracking

The former Homeland Security secretary and Arizona governor also talks about security improvements since the Sept. 11 attacks, and the frustrations and potential solutions to the immigration debate.
NPR

Kids And Screen Time: Cutting Through The Static

One Los Angeles school is working technology into the learning process, while avoiding the traditional screen-time pitfalls.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.